ArticleJournal of cosmetic dermatology2025
EYE-CODE Protocol for the Nonophthalmologist for Treatment of Retinal Artery Occlusion After Intra-Arterial Injection of Soft-Tissue Fillers: 2025 Update.
Article in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Consensus Guidelines for the Management of Tissue Filler-Induced Vision Loss in the United Kingdom.Aesthetic surgery journal · 2026Guideline
- Single-Center Retrospective Case Series of 33 Patients with Ophthalmic-Cerebral Embolic Stroke Following Cosmetic Facial Injection, 2017-2025.Healthcare (Basel, Switzerland) · 2026Article
- Guide for Managing Vascular Occlusion Due to Fillers with Extended Neuro-Ophthalmic Involvement: A Review of Diagnosis, Classification and Treatment.Aesthetic plastic surgery · 2026Review
- EYE-CODE Protocol for the Nonophthalmologist for Treatment of Retinal Artery Occlusion After Intra-Arterial Injection of Soft-Tissue Fillers: 2025 Update.Journal of cosmetic dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVision loss following a facial esthetic procedure with soft-tissue fillers is an event for which there is only a short treatment window to restore blood flow before irreversible ischemic damage occurs.
objectiveTo provide a current standardized treatment approach for the management of retinal artery occlusion after intra-arterial injection of soft-tissue fillers.
methodsThis document provides an updated, simple, and evidence-based protocol for acute treatment in the office setting using the acronym EYE-CODE: EYE (I call retinal referral center), C (check vision and optic nerve function), O (ocular massage), D (decrease intraocular pressure), and E (erase filler).
resultsThe EYE-CODE protocol assists esthetic physicians to determine the extent of vision loss and provides an initial treatment strategy using medications likely to be available in most practices. This includes agents that reduce intraocular pressure, improve retinal perfusion, and potentially dissolve the filler embolus and any associated blood clots. Suggestions are also made for treatments that can be continued by an emergency ophthalmologist.
conclusionThe EYE-CODE 2025 update provides physicians with a comprehensive reference for the management of retinal artery occlusion caused by soft-tissue filler injections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.